Nuvation Bio (NUVB) Reiterated at Market Outperform by Citizens Amid Acquisition by GSK
Tweet Send to a Friend
Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
